Shots:
- FDA has approved Wegovy HD (7.2mg semaglutide, QW) under CNPV along with lifestyle intervention for chronic weight management in adults with obesity; Wegovy HD will be launched as a single-dose pen by Apr 2026
- Backed by STEP UP trial (~1,400 adults without T2D) & STEP UP T2D trial (~500 obese adults with T2D), based on efficacy estimand, Wegovy HD achieved 20.7% mean weight loss in STEP UP, with 1/3 pts losing ≥25%, while in STEP UP T2D, mean weight loss was 14.1%, with 21.3% achieving ≥20% weight loss
- Additionally, regulatory review for semaglutide 7.2mg is ongoing in the EU & the UK as a single-dose pen, with decision expected by the H2’26
Ref: Novo Nordisk| Image: Novo Nordisk | Press Release
Related News: Novo Nordisk and Vivtex Partner in ~2.1B Metabolic Deal to Develop Oral Therapies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
